Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy
BACKGROUND: Outpatient cancer chemotherapy may lead to improved quality of life (QOL) by allowing treatment to continue without impairing the social lives of patients compared with hospitalization. However, the occurrence of serious adverse events may cause a decline in QOL. We investigated the rela...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686000/ https://www.ncbi.nlm.nih.gov/pubmed/32281034 http://dx.doi.org/10.1007/s00520-020-05443-8 |
_version_ | 1783613277570334720 |
---|---|
author | Hirose, Chiemi Fujii, Hironori Iihara, Hirotoshi Ishihara, Masashi Nawa-Nishigaki, Minako Kato-Hayashi, Hiroko Ohata, Koichi Sekiya, Kumiko Kitahora, Mika Matsuhashi, Nobuhisa Takahashi, Takao Okuda, Kumiko Naruse, Masayo Ishihara, Takuma Sugiyama, Tadashi Yoshida, Kazuhiro Suzuki, Akio |
author_facet | Hirose, Chiemi Fujii, Hironori Iihara, Hirotoshi Ishihara, Masashi Nawa-Nishigaki, Minako Kato-Hayashi, Hiroko Ohata, Koichi Sekiya, Kumiko Kitahora, Mika Matsuhashi, Nobuhisa Takahashi, Takao Okuda, Kumiko Naruse, Masayo Ishihara, Takuma Sugiyama, Tadashi Yoshida, Kazuhiro Suzuki, Akio |
author_sort | Hirose, Chiemi |
collection | PubMed |
description | BACKGROUND: Outpatient cancer chemotherapy may lead to improved quality of life (QOL) by allowing treatment to continue without impairing the social lives of patients compared with hospitalization. However, the occurrence of serious adverse events may cause a decline in QOL. We investigated the relationship between outpatient chemotherapy–induced adverse events and QOL. METHODS: A single-center retrospective descriptive study was conducted in patients who received outpatient chemotherapy at Gifu University Hospital (Gifu, Japan) between September 2017 and December 2018. The utility values of QOL, type and severity of adverse events, type of cancer, chemotherapy regimen, and other patient demographics were analyzed. Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 4.0. QOL was evaluated using the Japanese version of the EuroQol 5 Dimension 5 Level (EQ-5D-5L). Associations between the EQ-5D-5L utility value and serious adverse events were assessed using adjusted (age and sex) odds ratios obtained with a proportional odds logistic regression model. RESULTS: Data from 1008 patients who received 4695 chemotherapy cycles were analyzed. According to proportional odds logistic regression, the adverse events that significantly correlated with a decreased EQ-5D-5L utility value were malaise, edema of the limbs, peripheral neuropathy, pruritus, and dry skin. Based on the proportional odds logistic analysis, neither cancer type nor anticancer drugs were significantly correlated with the EQ-5D-5L utility value in patients who received chemotherapy. Pharmaceutical care for peripheral neuropathy significantly improved patients’ EQ-5D-5L utility value from 0.747 to 0.776 (P < 0.01). CONCLUSIONS: Adverse events (i.e., peripheral neuropathy, malaise, and edema of the limbs) are significantly correlated with a decrease in QOL, regardless of the type of cancer or anticancer drugs used. Pharmaceutical care provided by pharmacists in collaboration with physicians may improve QOL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00520-020-05443-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-7686000 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-76860002020-11-30 Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy Hirose, Chiemi Fujii, Hironori Iihara, Hirotoshi Ishihara, Masashi Nawa-Nishigaki, Minako Kato-Hayashi, Hiroko Ohata, Koichi Sekiya, Kumiko Kitahora, Mika Matsuhashi, Nobuhisa Takahashi, Takao Okuda, Kumiko Naruse, Masayo Ishihara, Takuma Sugiyama, Tadashi Yoshida, Kazuhiro Suzuki, Akio Support Care Cancer Original Article BACKGROUND: Outpatient cancer chemotherapy may lead to improved quality of life (QOL) by allowing treatment to continue without impairing the social lives of patients compared with hospitalization. However, the occurrence of serious adverse events may cause a decline in QOL. We investigated the relationship between outpatient chemotherapy–induced adverse events and QOL. METHODS: A single-center retrospective descriptive study was conducted in patients who received outpatient chemotherapy at Gifu University Hospital (Gifu, Japan) between September 2017 and December 2018. The utility values of QOL, type and severity of adverse events, type of cancer, chemotherapy regimen, and other patient demographics were analyzed. Adverse events were graded according to the Common Terminology Criteria for Adverse Events, version 4.0. QOL was evaluated using the Japanese version of the EuroQol 5 Dimension 5 Level (EQ-5D-5L). Associations between the EQ-5D-5L utility value and serious adverse events were assessed using adjusted (age and sex) odds ratios obtained with a proportional odds logistic regression model. RESULTS: Data from 1008 patients who received 4695 chemotherapy cycles were analyzed. According to proportional odds logistic regression, the adverse events that significantly correlated with a decreased EQ-5D-5L utility value were malaise, edema of the limbs, peripheral neuropathy, pruritus, and dry skin. Based on the proportional odds logistic analysis, neither cancer type nor anticancer drugs were significantly correlated with the EQ-5D-5L utility value in patients who received chemotherapy. Pharmaceutical care for peripheral neuropathy significantly improved patients’ EQ-5D-5L utility value from 0.747 to 0.776 (P < 0.01). CONCLUSIONS: Adverse events (i.e., peripheral neuropathy, malaise, and edema of the limbs) are significantly correlated with a decrease in QOL, regardless of the type of cancer or anticancer drugs used. Pharmaceutical care provided by pharmacists in collaboration with physicians may improve QOL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00520-020-05443-8) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-04-12 2020 /pmc/articles/PMC7686000/ /pubmed/32281034 http://dx.doi.org/10.1007/s00520-020-05443-8 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Original Article Hirose, Chiemi Fujii, Hironori Iihara, Hirotoshi Ishihara, Masashi Nawa-Nishigaki, Minako Kato-Hayashi, Hiroko Ohata, Koichi Sekiya, Kumiko Kitahora, Mika Matsuhashi, Nobuhisa Takahashi, Takao Okuda, Kumiko Naruse, Masayo Ishihara, Takuma Sugiyama, Tadashi Yoshida, Kazuhiro Suzuki, Akio Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy |
title | Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy |
title_full | Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy |
title_fullStr | Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy |
title_full_unstemmed | Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy |
title_short | Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy |
title_sort | real-world data of the association between quality of life using the euroqol 5 dimension 5 level utility value and adverse events for outpatient cancer chemotherapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7686000/ https://www.ncbi.nlm.nih.gov/pubmed/32281034 http://dx.doi.org/10.1007/s00520-020-05443-8 |
work_keys_str_mv | AT hirosechiemi realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT fujiihironori realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT iiharahirotoshi realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT ishiharamasashi realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT nawanishigakiminako realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT katohayashihiroko realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT ohatakoichi realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT sekiyakumiko realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT kitahoramika realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT matsuhashinobuhisa realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT takahashitakao realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT okudakumiko realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT narusemasayo realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT ishiharatakuma realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT sugiyamatadashi realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT yoshidakazuhiro realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy AT suzukiakio realworlddataoftheassociationbetweenqualityoflifeusingtheeuroqol5dimension5levelutilityvalueandadverseeventsforoutpatientcancerchemotherapy |